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Purpose: The purpose of this study was to histologically and immunohistochemically 
evaluate bone regeneration using three different implant materials in rabbit mandibles 
and also to compare the bone regenerative capability of these materials in an animal 
model.  
Study design: Adult male Japanese white rabbits (n=48, 12-16 weeks, 2.5-3.0 kg) were 
divided into four groups, consisting of twelve animals each.  The implant materials were 
β-tricalcium phosphate (β-TCP), autologous bone derived from the radius, and 
recombinant human bone morphogenetic protein-2 (rhBMP-2) with polylactic 
acid/polyglycolic acid copolymer and gelatin sponge (PGS) complex. After incising 
along the inferior border of mandible, the materials were implanted as onlay grafts and 
covered by titanium mesh with screws. No material was implanted into the control group. 
The rabbits were sacrificed at 2, 4, 8, 12 and 24 weeks postoperatively, and 
formalin-fixed specimens containing titanium mesh were embedded in acrylic resin. The 
specimens were stained with hematoxylin and eosin. For immunohistochemical analysis, 
the specimens were treated with BMP-2 (bone morphogenetic protein-2) and FGF-2 
(fibroblast growth factor-2) antibodies. Finally, these were evaluated microscopically. 
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Results: The autologous bone induced substantially more new bone formation compared 
to β-TCP at 4 weeks postoperatively. However, rhBMP-2/PGS induced new bone 
formation at 8 weeks postoperatively. No growth of bony tissue was observed in the 
control group at any period. In the autologous bone and rhBMP-2/PGS groups, both 
BMP-2 and FGF-2 appeared specifically at the operated sites at early stages, but 
expression of BMP-2 and FGF-2 was observed later in the β-TCP group than in other 
experimental groups. 
Conclusion: This study suggested that autologous bone as well as rhBMP-2/PGS 
implants induced expression of both BMP-2 and FGF-2 specifically at the operated sites 





Restoration of bone is often required after dental and oral surgical procedures. 
Treatment of cysts, tumors, and fractures of the jaw can result in bone defects. Such 
defects must be repaired with bone grafts or bone substitutes to ensure good structural 
and functional outcomes1. In the recent years, bone grafts and bone substitutes 
underneath barrier membranes have been increasingly utilized to optimize the treatment 
outcome of bone reconstructive therapy for defects in the alveolar process. 
Conventionally, fresh autologous bone grafts are used to repair oral and maxillofacial 
bone defects. However, the need for a second surgery at the donor site and the limited 
availability of bone has led to the development of various alternative materials to 
autologous bone grafts such as β-TCP and BMPs. 
β-tricalcium phosphate (β-TCP) is a calcium phosphate type material that 
promotes osteogenesis and is also replaced by bony tissue through a process of 
dissolution and absorption, finally achieving a normal bone structure2,3 However, there 
are no reports about the use of β-TCP as an onlay bone graft material in mandibles. 
Bone morphogenetic proteins (BMPs) are active bone-inducing factors that act 
on immature mesenchymal cells, including osteoblasts, resulting in osteogenesis. To 
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date, several types of BMPs have been isolated by molecular cloning and recombinant 
BMP molecules have been synthesized4. Recombinant human BMP-2 (rhBMP-2) is a 
molecule that has strong bone-inducing capability in vivo5. However, to optimize 
delivery at the bone repair site, rhBMP-2 requires a suitable carrier. Recently, a 
synthetic polymer, polylactic acid/polyglycolic acid copolymer and gelatin sponge 
(PGS), that acts as an effective carrier for rhBMP-2 has been developed6. 
Basic fibroblast growth factor (FGF-2) is a component of the bone matrix that 
plays a role in regulating bone remodeling7. Recent reports have shown that the addition 
of exogenous FGF-2 to a fracture site or bone defect during the early healing stage 
accelerates fracture repair and bone formation8. However, no experimental studies have 
been performed to investigate the expression of FGF-2 during bone regeneration. 
Moreover, the association between the expression of rh-BMP-2 and FGF-2 in 
mandibular regeneration has not been previously examined. 
 The purpose of this study was to histologically and immunohistochemically 
evaluate bone regeneration using β-TCP, autologous bone and rhBMP-2 with PGS 
implant materials in rabbit mandibles and also to compare the bone regenerative 
capability of these materials in an animal model. 
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 Materials and Methods 
 
The experimental protocol was approved by the Institutional Committee for 
Animal Care, Kanazawa University. 
 
Experimental animals 
Forty-eight male Japanese white rabbits (12-16 weeks, 2.5-3.0 kg) were 




 The entire procedure was performed under sterile conditions. First, the animals 
were anesthetized with sodium pentobarbital (25 mg/kg) by injection into the lateral ear 
vein. After the hair in the submandibular region was shaved, 1.8 ml of 2% lidocaine 
containing 1:80,000 epinephrine was administered to the surgical site. A 25 mm 
horizontal skin incision was made over the submandibular region to expose the margin of 
the left mandibular body. The skin, muscles and periosteum were incised along the 
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inferior border of the mandible and subperiosteal space to accommodate the implant on 
the buccal aspect of the ramus (Fig. 1). 
 
Implant materials 
 The implant materials were β-TCP, autologous bone and rhBMP-2 with PGS 
(rhBMP-2/PGS).  These materials were implanted as onlay grafts, covered by titanium 
mesh (3×3×10 mm cube), and secured with titanium screws. The grafts were secured to 
the lateral aspect of the mandible with a single titanium screw that was 7mm in length and 
1.5 mm in diameter. β-TCP (Olympus Optical, Tokyo, Japan) was porous in the form of a 
3×3×10 mm cube, with an average weight of 0.07 g. Autologous bone was derived from 
the radius bone. For this, the right radius was exposed via a skin incision and reflexion of 
a facial periosteal flap. A bone segment (length 2.5 cm) was oseotomized from the radius 
using a diamond drill under copious saline irrigation. The bone graft was preserved in a 
moist gauge while preparing the recipient site. The rhBMP-2 and PGS were provided by 
Yamanouchi Pharmaceutical Co, Ltd, Japan. The rhBMP-2 was suspended in a buffer 
(pH 4.5) consisting of 5 mM L-glutamic acid, 2.5% glycine, 0.5% sucrose, and 0.01% 
Tween 80 (Difco Laboratories, Detroit, MI, USA). It was kept at a temperature of –80ºC 
until needed, when it was thawed at room temperature. The PGS was cut into 5×5×10 
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mm3 blocks. In the rhBMP-2/PGS implants, 5 μg rh-BMP-2 was combined with 250 mm3 
of PGS. This mixture was lyophilized before it was implanted into the animals along the 
inferior border of mandible.  No material was implanted in the control group. In control 




 The rabbits were sacrificed at 2, 4, 8, 12 and 24 weeks postoperatively and the 
specimens containing the titanium mesh were collected for hematoxylin and eosin 
staining and also for immunohistochemical analysis. 
 
Histological examination 
After fixation with 10% phosphate-buffered formalin, the specimens with the 
titanium mesh were dehydrated in ethanol and technovit 7200VCL (Kultzer and Co., 
GmbH, Wehreim, Germany) and then embedded in acrylic resin. The embedded blocks 
were trimmed by cutter and ground by abrasive paper. Thereafter, the sections were 
further ground to a final thickness of about 10 μm. Finally, the specimens were stained 
with hematoxylin and eosin and examined under microscope. 
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 Immunohistochemical staining 
The prepared sections were deacrylated in 2-methoxyethyl acetate, inhibited by 
endogenous peroxidase with 0.3% hydrogen peroxide and blocked in 10% normal 
serum prior to staining. For immunostaining, commercially available monoclonal 
anti-BMP-2 antibodies (Yamanouchi Seiyaku Inc., Tokyo, Japan) and anti-FGF-2 
antibodies (Takeda Chemical Industries, Osaka, Japan) were used. Sections were 
incubated overnight with these primary antibodies at 4ºC in a humidified chamber. A 
biotinylated goat anti-mouse IgG antibody (Wako Junyaku Inc., Osaka, Japan) was used 
as the secondary antibody. The Vectastain-Elite ABC kit detection system, DAB 
revelation kit and DAB enhancing solution (Wako Junyaku Inc., Osaka, Japan) were 
used to complete the immunostaining. Finally, a light Meyer’s hematoxylin counter 
stain was applied. The sections were then dehydrated in alcohol and mounted for light 
microscopy to count the number of positively stained active cells in the regeneration site. 
The observation area was located between the superior point and the most inferior point 
of titanium mesh curve and in coronal section (Fig.2). The number of stained cells per 
voluntary 1000 cells in this area was counted by hand using high magnification 
photomicrograph (×100). 
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 Statistical Analysis  
Data of all the implanted materials were statistically analyzed with Stat View 4.5 
(ABACUS Concepts, Inc., Berkeley, CA, USA). Differences between groups were 
analyzed by non-paired comparison using Scheffe’s F test. Time-dependent changes 
were examined by analysis of variance (ANOVA). Differences were considered 
significant at P< 0.05. 
 
Results 
Healing progressed uneventfully in all animals and no postoperative 
complications were noted during the 24-week observation period. After resting for 3-6 




In the β-TCP group, chondrocytes appeared 2 weeks after the operation. From 
4 weeks, active osteoblasts appeared with the remaining β-TCP (Fig. 3) and by 8 weeks, 
woven bone was formed. From 12 weeks, mature bone formation was observed and by 
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24 weeks, mature lamellar bone was clearly stained with eosin. 
In the autologous bone group at 2 weeks, the operated surface was covered 
with fibrous tissue. From 4 weeks, more osteoblast cells became active (Fig. 4). After 8 
weeks, bone resorption and new bone formation were observed at the recipient site in 
the contact area to the graft. After 12 weeks, bone remodeling activity and new bone 
was noted at the graft. After 24 weeks, the resorption had continued. 
In the RhBMP-2/PGS group at 2 weeks, the operated area was partially 
covered with fibrous tissue. At 4 weeks, the operated area was not restored completely 
and residual PGS was still visible (Fig. 5). However, osteoblasts and fibroblasts were 
observed under the implant. After 8 weeks, trabeculae of new bone extended towards 
the internal surface of the operated area, which was still thin and primitive. At 12 weeks, 
the lamellar structure had developed well in the newly formed bone and the trabecular 
bone was thicker than it was at 8 weeks. Remodeling and consolidation of the new bone 
were also observed within the operated area. At 24 weeks, mature bone was clearly 
observed. 




β-TCP bone grafting treated with BMP-2 antibody 
At 2 weeks, a few positive stained cells were observed. After 4 weeks, there 
were positive stained cells and a few bone forming cells (Fig. 6A). After 8 weeks, there 
was slight new bone formation. At 12 and 24 weeks, bone formation was more clearly 
observed, but the number of positive stained cells decreased gradually with time (Fig. 
6B). 
 
β-TCP bone grafting treated with FGF-2 antibody  
The results were nearly the same as those after treatment with BMP-2 antibody 
(Figs. 6C, D). 
 
Autologous bone grafting treated with BMP- 2 antibody 
At 2 weeks, positive stained cells were observed. After 4 weeks, there were 
more positive stained cells accompanied by new bone formation with preservation of 
the graft bone (Fig. 7A). New bone formation was observed over time, which increased 




Autologous bone grafting treated with FGF-2 antibody  
Results were the same as in case of staining with BMP-2. We could see both 
positive stained cells and new bone formation at 4 weeks (Fig. 7C). But the number of 
positive stained cells decreased gradually at 8 weeks and reached a minimum at 24 
weeks (Fig. 7D) 
  
rhBMP-2/PGS bone grafting treated with BMP-2 antibody  
At 2 weeks, positive stained cells were observed. At 4 weeks, there were many 
positive stained cells (Fig. 8A). New bone formation also increased gradually and 
reached a peak at 24 weeks (Fig. 8B), but the number of positive stained cells markedly 
decreased and reached the minimal level by this time. 
 
rhBMP-2/PGS bone grafting treated with FGF-2 antibody  
The results were nearly the same as those after treatment with BMP-2 antibody 
(Figs. 8C, D). 
 
Control group treated with BMP-2 and FGF-2 antibodies 
In both cases, fewer positive stained cells were observed compared to the 
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experimental groups. However, we observed fibrous tissue in the earlier period, whereas 
little new bone formation was observed later. (Figs. 9A, B, C, D). 
Statistical measurements 
All resuls of the statistical measurements are presented in Table 1 and Fig 
10,11. 
For BMP-2 antibody, the time-course changes showed statistically significant 
differences by repeated measure ANOVA (between subjects; F=28.222, df=12, 
P<0.0001; within subjects; F=120.132, df=4, P<0.0001). 
In the immunohistochemical examination after treatment with BMP-2 antibody, 
when autologous group was compared with control and β-TCP groups, the cell numbers 
significantly increased after 2, 4 and 8 weeks (P<0.05). However, when autologous 
group was compared with only rhBMP-2/PGS group, cell numbers were found 
significantly high only at 4 weeks (P<0.05) (no positive cells were found at 2 and 8 
weeks). Similarly, when rhBMP-2/PGS was compared with control and β-TCP, the cell 
numbers were significantly higher at 2, 4 and 8 weeks (P<0.05). But there was no 
significant difference between control and β-TCP in cell number for 2, 4 and 8 weeks. 
However, in all groups, no positive cells were detected at 12 and 24 weeks (Fig. 10 and 
Table 1). 
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For FGF-2 antibody, the time-course changes showed statistically significant 
differences by repeated measure ANOVA (between subjects; F=7.965, df=12, P<0.0001; 
within subjects; F=36.997, df=4, P<0.0001). 
In the immunohistochemical examination after treatment with FGF-2 antibody, 
when rh BMP2/ PGS group was compared with the autologous, control and β-TCP 
groups, the cell numbers significantly increased at 2, 4 and 8 weeks (P<0.05). Similarly, 
when the control group was compared with the autologous and β-TCP groups, cell 
numbers were found significantly increased only at 4 weeks (P<0.05). However, 
comparison between the autologous and β-TCP groups indicated that no positive cells 
were detected at any of the periods. In all groups, no significant difference was detected 
at 12 and 24 weeks (Fig. 11 and Table 1). 
Thus, in the cell number stained by both BMP-2 and FGF-2 antibodies, similar 




The ability of bone grafts to increase osteogenesis is important in maxillofacial 
surgery, because an increase in healing rate can decrease the time of intermaxillary 
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fixation. However, only a few graft materials actually increase osteogenesis. This can be 
done in two ways: (1) by providing viable cells that are either osteoblasts or can 
differentiate into osteoblasts, and (2) by inducing host tissue to increase the number of 
osteoblasts. These two effects have been termed osteogenetive and osteoinductive9,10 
respectively..  
 In the present study, we evaluated bone regeneration using three different 
implant materials and also compared the bone regenerative capability of these materials 
in an animal model histologically and immunohistochemically. In this study, a titanium 
mesh of same size was used in all groups in order to create same space for bone 
regeneration under different implant materials. The rigid titanium mesh could maintain 
the space for bone regeneration under the same dynamic situation. Although, it was a 
limitation of the model that the cortical border of the mandible was perforated by the 
mesh retention screws, but it was necessary to fix the experimental materials. However, 
our observation area was difference from perforation site, so that this study could be 
evaluated objectively.  This study showed that new bone was formed following the 
implantation of all types of implant materials. 
 Although we used titanium mesh in our study, calcium phosphate type β-TCP 
has been used as artificial bone. β-TCP promotes osteogenesis and is replaced by 
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autologous bone in the course of dissolution and absorption 3,11,12,13, finally achieving a 
normal bone structure. However, Saito et al.14 reported that the periosteum had 
osteoinduction capacity while β-TCP had osteoconduction capacity and that better 
osteogenesis occurred with vascularized periosteum. They also suggested that bone 
marrow fluid was involved in the promotion of osteoblastic activity, but not in 
calcification. It has been suggested that newly formed bone infiltrates and binds with the 
indented part of the dissolved β-TCP; thereby a mechanical bond exists between β-TCP 
and bone12. Since no chemical bond is present, the β-TCP gradually dissolves, even when 
osteogenesis progresses around the β-TCP. However, in our study, regeneration rate was 
slow and β-TCP remained after the implantation of β-TCP. It has been reported that 
β-TCP is replaced by bone when it is implanted in bone marrow2,3,.14. It does not remain 
as a foreign body and is absorbed. At present, calcium phosphate type hydroxyapatite 
(HA), which is considered to promote osteogenesis, is generally used as artificial bone. 
However, HA has a disadvantage: it shows almost no absorption and remains in the body 
for a long time as a foreign substance15. Therefore, we focused our attention on β-TCP, 
which is a calcium phosphate type material, and used it in the present study. 
Autologous onlay bone grafts have been used in the craniofacial skeleton to 
repair bony deficiencies in those afflicted with congenital anomalies or in those who 
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have sustained traumatic injuries. This type of graft is considered the most compatible 
of the materials available. An experimental rabbit model, in which the radius bone is 
transplanted onto the mandibular lower border, has been successfully tested for the 
study of endosseous implants placed into onlay grafts16. This model also provides the 
conditions for the study of graft-host bone integration under critical revascularization 
conditions, since the radius is almost devoid of cancellous bone. Difficulties may arise 
in the prediction of maintenance of graft volume over time when bone grafts are used 
for facial contour reconstruction. Therefore, we hypothesize that graft fixation will 
decrease movement and lead to decreased resorption. John et al.17 reported that when 
onlay bone grafts are stabilized, improved results with respect to graft resorption can be 
expected. The method of autologous bone graft was different from previous reports, so 
that it was difficult to compare with previous report. Kahnberg et al.16stated that after 6 
weeks osteoclastic and osteoblastic activity was primarily observed in the graft-recipient 
contact area. In our study, new bone formation with titanium mesh and screw was 
observed after 4 weeks. New bone formation using mesh fixation might occur earlier 
than others.  
 In vivo, among subperiosteal implantation sites, BMP induces new bone 
formation in heterotrophic, intermuscular and orthotropic sites18,19. In vitro, BMP 
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induces cartilage formation in neonatal muscle tissue20,21,22. It is thought that BMP 
induces differentiation of prevascular mesenchymal connective tissue cells into bone 
and cartilage. Various preparations of BMP have been reported to initiate new bone 
formation when implanted in animals, but there have been few reports of BMP implants 
in alveolar defects of mandible to induce osteogenesis at intraskeletal sites23,24. The use 
of BMP at the submandibular region has not been reported so far.  
BMPs may initiate all of the molecular mechanisms required for bone 
induction, including the orderly migration, proliferation and differentiation of 
osteoprogenitors and undifferentiated mesenchymal cells into functional osteoblasts. 
New bone formation by bone inductive protein depends on the quantity of the BMPs 
and the delivery system or carrier. BMP activity is greatest when it is placed with a 
suitable carrier. Several carriers with suitable characteristics have been developed25,26,27. 
An ideal carrier is not only bioresorbable and non-immunogenic, but also provides a 
three dimensional structure as a scaffold for new bone formation. It has been reported 
previously that the polylactic acid/polyglycolic acid (PLGA) gelatin sponge (PGS) 
copolymer is an effective carrier for BMPs28,29. So PGS has been successfully used for 
bone repair with rhBMP-2 in bone defect models of periodontal tissues, mandible and 
ulna in experimental animals30,31,32.. PGS can play an important role perhaps by acting 
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as a space retainer and shock absorber during the formation of new bone. Hence, we 
used PGS as a carrier for rhBMP-2. Mao et al. 33 reported that at 12 weeks the 
composite using rhBMP with chitin, coral or xenogenetic cancellous bone was replaced 
completely by new bone. In our study, the new bone formation with rhBMP/PGS was 
observed after 8 weeks earlier than previous reports. This might be due to difference in 
carrier material and titanium mesh to maintain the regeneration space. 
When the results of this study are adapted to human, we have to consider some 
factors to affect the bone formation. Firstly, there was difference in turn over period 
between rabbit and human. We did not know whether the follow up period of this study 
was valid or not. However, on the basis of previous rabbit study, it seemd to be 
significanly long. There are numerous parameters that can influnce the outcome of 
onlay bone grafts. For example, rigid fixation, degree of graft contact with the recipient 
surface, properties of the recipient bed and size of bone graft, prevention of bacterial 
infection are all very relevant. Above these parameters are depend on success or failure 
examined both of human and animal study for bone regeneration. Because of the above 
phenomena, the patterns of bone formation in the three groups in our study were 
different. Our study was the duration follow-up at six months. During these periods 
bone regeneration was observed better. This study would helpful for clinician. 
 20 
  
. Our immunohistochemical studies demonstrated that BMP-2 was strongly 
expressed in the connective tissue of the gap, after implantation on the rabbit mandible. 
Bone marrow was also strongly stained at the edge of the osteogenesis site. FGF-2 
expression followed a similar pattern to that of BMP-2 specifically at the edge of the 
osteogenesis site. 
   In the control group, the tissues that formed were a variable mixture of fibrous 
tissue formed by mesenchymal cells derived from the open marrow space, but little bone 
formation was observed, 
. 
 Our study statistical analysis revealed BMP-2 with PGS  and autologous group 
expression levels were higher than in the other groups  2, 4 an 8 weeks after BMP2 and 
FGF 2 antibody  treated. But it decreased both 12  and 24 weeks.However, β-TCP and 
control group  expression level were not well changed  at all period after treated with 
BMP-2 and FGF-2 treated. Hence, we conclude that autologous bone as well as 
rhBMP-2/PGS implants induced expression of both BMP-2 and FGF-2 specifically at the 
operated sites in early stages. 
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FIGURE 1. Intra-operative finding: (A) Mandible exposed at the submandibular region, 
(B) Fixation of titanium mesh with different materials. 
 
FIGURE 2. Area of immunohistochemical observation (indicated by triangle) located 
between the superior point and the most inferior point of titanium mesh curve. 
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FIGURE 3. β-TCP group histopathological findings at 4 weeks. New bone was formed 
around the remaining β-TCP (hematoxylin-eosin, original magnification×40). B: 
β-TCP, M: mandible, NB: new bone, T: titanium mesh. 
 
FIGURE 4. Autologous bone group histopathological findings at 4 weeks. New bone 
was formed (hematoxylin-eosin, original magnification×40). NB: new bone, T: 
titanium mesh. 
 
FIGURE 5. rhBMP-2/PGS group. Histopathological findings at 4 weeks. There was 
new bone formation around the remaining PGS (hematoxylin-eosin, original 
magnification ×40). PGS: polylactic acid/polyglycolic acid copolymer and gelatin 
sponge. 
 
FIGURE 6. Photomicrographs of β-TCP group. Stained with BMP-2 antibody at 4 
weeks (A), and at 24 weeks (B). Stained with FGF-2 antibody at 4 weeks (C), and at 24 
weeks (D). (Immunohistochemical staining, original magnification ×200). B: β-TCP, 
I: implant, NB: new bone, P: positive cell area. 
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FIGURE 7. Photomicrographs of autologous bone group. Stained with BMP-2 antibody 
at 4 weeks (A), and at 24 weeks (B). Stained with FGF-2 anybody at 4 weeks (C), and 
at 24 weeks (D). (Immunohistochemical staining, original magnification ×200). GB: 
graft bone, NB: new bone, P: positive cell area.  
 
FIGURE 8. Photomicrographs of rhBMP-2/PGS group. Stained with BMP-2 antibody 
at 4 weeks (A), and at 24 weeks (B). Stained with FGF-2 antibody at 4 weeks (C), and 
at 24 weeks (D). (Immunohistochemical staining, original magnification ×200). NB: 
new bone, P: positive cell area. 
 
FIGURE 9. Photomicrographs of control group. Stained with BMP-2 antibody at 2 
weeks (A), and at 12 weeks (B). Stained with FGF-2 antibody at 2 weeks (C), and at 12 
weeks (D). (Immunohistochemical staining, original magnification ×200). F: fibrous 
tissue, P: positive cell area. 
 
FIGURE 10. The ratio of BMP-2 positive cells. The time course changes in all groups 
showed significant differences with ANOVA.  
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FIGURE 11. The ratio of FGF-2 positive cells. The time course changes in all groups 
showed significant differences with ANOVA.  
 
Table 1. The results of statistical analysis with Scheffe’s F test.  

























































































































BMP2 antibody Weeks 2 4 8 12 24
Autologous bone vs rhBMP/PGS NS S NS NS NS
Autologous bone vs Control S S S NS NS
Autologous bone vs β-TCP S S S NS NS
rhBMP/PGS vs Control S S S NS NS
rhBMP/PGS vs β-TCP S S S NS NS
Control vs β-TCP NS NS NS NS NS
FGF2 antibody Weeks 2 4 8 12 24
Autologous bone vs rhBMP/PGS S S S NS NS
Autologous bone vs Control NS S NS NS NS
Autologous bone vs β-TCP NS NS NS NS NS
rhBMP/PGS vs Control S S S NS NS
rhBMP/PGS vs β-TCP S S S NS NS
Control vs β-TCP NS S NS NS NS
Table 1
